

REMARKS/ARGUMENTS

In response to the Final Office Action mailed July 28, 2008, Applicants propose to amend their application and request reconsideration in view of the proposed amendments and the following remarks. In this amendment, Claim 1 is amended, no new claims have been added and no claims have been cancelled without prejudice so that Claims 1-4 remain pending. No new matter has been introduced.

Claims 1-4 were rejected as being anticipated by U.S. Patent Publication No. US2004/0037886 to Hsu. This rejection is respectfully traversed.

Application exists only if all of the elements of the claimed invention are present in a system or method disclosed, expressly or inherently, in a single prior art reference. Therefore, if it can be shown that there is one difference between the claimed invention and what is disclosed in the single reference, there can be no anticipation.

Independent Claim 1 has been amended to more precisely claim the subject matter. Claim 1 is directed to the utilization of sirolimus and Panzem® as set forth in the specification. In addition, sirolimus is a rapamycin. As shown in Figure 68, this unique combination is more effective than either drug alone (See paragraphs 278-280 of this present application.) Accordingly, reconsideration and withdrawal of the rejection is respectfully requested.

A favorable action on the merits is earnestly solicited.

Respectfully submitted,

/Carl J. Evens/

By: _____
Carl J. Evens
Reg. No. 33,874

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2518
Dated: September 16, 2008